Agilent Technologies (A) vs 10x Genomics (TXG)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 7, 2026.
Summary
10x Genomics (TXG) has outperformed Agilent Technologies (A) over the past year, gaining 556.0% versus a gain of 22.0%. Over five years, A leads with a +10.3% price change compared with -50.0% for TXG. Agilent Technologies is the larger company by market cap ($47.68 billion vs $9.92 billion), about 4.8 times the size.
On valuation, Agilent Technologies trades at a lower forward P/E (25.0x vs 992.6x for 10x Genomics). Agilent Technologies pays a dividend yielding 0.60%, while 10x Genomics does not currently pay one. Agilent Technologies converts more of its revenue into profit, with a net margin of 18.8% versus -6.8%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | A | TXG |
|---|---|---|
| Share price | $169.09 | $76.10 |
| Market cap | $47.68B | $9.92B |
| 1-day change | -0.14% | -5.65% |
| YTD return | +24.27% | +366.58% |
| 1-year return | +22.03% | +556.03% |
| 5-year return | +10.32% | -50.02% |
| P/E ratio (TTM) | 33.35 | — |
| Forward P/E | 25.02 | 992.57 |
| EPS (TTM) | $5.07 | $-0.59 |
| Dividend yield | 0.60% | 0.00% |
| Annual dividend | $1.01 | $0.00 |
| Revenue (latest FY) | $6.95B | $642.82M |
| Revenue growth (YoY) | +6.73% | +5.25% |
| Net income (latest FY) | $1.30B | $-43.54M |
| Gross margin | 52.43% | 69.05% |
| Operating margin | 21.29% | -9.49% |
| Net margin | 18.75% | -6.77% |
| 52-week high | $177.05 | $102.81 |
| 52-week low | $108.35 | $11.16 |
| Distance from 52-week high | -4.50% | -25.98% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +4.38% | -13.27% |
| Average volume | 2.26M | 3.15M |
| Shares outstanding | 281.97M | 120.21M |
| Employees | 18,200 | 1,178 |
| Sector | Industrials | Industrials |
| Industry | Biotechnology: Laboratory Analytical Instruments | Biotechnology: Laboratory Analytical Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Agilent Technologies is about 4.8 times larger than 10x Genomics by market value ($47.68B vs $9.92B).
- TXG has outperformed A by 534.0 percentage points over the past year.
- Agilent Technologies is more profitable, keeping 18.8 cents of every revenue dollar as net income versus -6.8 cents for 10x Genomics.
About Agilent Technologies
A stock →Agilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide.
Industrials · Biotechnology: Laboratory Analytical Instruments · 18,200 employees
About 10x Genomics
TXG stock →10x Genomics, Inc. develops and sells instruments, consumables, and software for analyzing biological systems in the United States, rest of the Americas, Europe, the Middle East, Africa, China, and the rest of the Asia Pacific.
Industrials · Biotechnology: Laboratory Analytical Instruments · 1,178 employees
A vs TXG FAQ
Which is bigger, Agilent Technologies or 10x Genomics?
Agilent Technologies (A) is larger, with a market capitalization of $47.68B compared with $9.92B for 10x Genomics (TXG).
Which stock has performed better over the past year, A or TXG?
TXG returned +556.03% over the past 12 months, compared with +22.03% for A (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, Agilent Technologies or 10x Genomics?
Agilent Technologies pays a dividend yielding 0.60%, while 10x Genomics does not currently pay a regular dividend.
Are Agilent Technologies and 10x Genomics in the same industry?
Yes. Both are classified in the Biotechnology: Laboratory Analytical Instruments industry within the Industrials sector.